Home/TauC3 Biologics/John S. Gogol

JS

John S. Gogol

Director

TauC3 Biologics

Therapeutic Areas

Neurodegenerative Diseases Frontotemporal Dementia Progressive Supranuclear Palsy

TauC3 Biologics Pipeline

Drug	Indication	Phase
Undisclosed Tau Immunotherapy	Tau-related Frontotemporal Dementia (FTD-tau)	Pre-clinical

Leadership Team at TauC3 Biologics

Bia Goncalves, PhD

Director of Scientific Communications

Scott Pollack, PhD

Scientific Leader (implied)

Chief Financial Officer

Michael P. Ross, PhD, CFA

Shafique Virani, MD

Richard A. Margolin, MD

Daniel G. Chain, PhD

Director/Scientific Founder

View full TauC3 Biologics profile